| Trial ID # | NCT04570839 |
| Phase | I/II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/TIGIT |
| Drug Name | BMS-986207 |
| Alternate Drug Names | anti-TIGIT monoclonal antibody BMS-986207 |
| Drugs in Trial | BMS-986207, COM701, Nivolumab |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 20; median 4 prior therapies (1-10) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Efficacy | ORR: 20% (4PR - 3 HGSOC, 1 OCCC) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | The combination of COM701 + BMS-986207 + nivolumab is well tolerated and has encouraging durable anti-tumor activity with immune activation in patients with platinum resistant HGSOC and OCCC |
| Reference | Gaillard S et al. Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer. J Immunother Cancer (2023) 11: abstract 669 Gaillard S et al. Poster |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.